|
|
| Home >> Medical Zone > Glizid M |
|
|
|
 |
 |
|
|
| GLIZID M |
| |
- Bajpai N, Gulati Aand Chatterjee A
A 4-6 Months Open Labelled, Multicentric, Non-comparative Study For Evaluation Of Efficacy, Safety And Tolerability Of Glizid-M In Type 2 Diabetes
Glizid-M is the fixed dose combination of Gliclazide (80mg) and Metformin (500mg) indicated for the treatment of non-insulin dependent diabetes mellitus; type 2 diabetes with or without obesity in adults. The present post marketing surveillan ce evaluated the efficacy, safety and tolerability of Glizid-M in 497 patients with type 2 diabetes. It was an open labelled, non-comparative, multi centric study; which involved 26 investigators across the country. The total duration of protocol therapy was 4 weeks, whereas duration of study was 4-6 months. Assessment of the blood glucose levels was performed at the baseline, at 2nd week and at the end of the therapy (4th week). Safety parameters were assessed at week 2 and at the end of the therapy.
- Bajpai N, Singh A P , Chatterjee A
An Open Labelled, Prospective, Non-comparative, Multicentric Post Marketing Experience for Evaluation of Efficacy and Safety of Glizid-M In Type 2 Diabetes.
Glizid-M is the fixed dose combination of Gliclazide (80mg) and Metformin (500mg). The efficacy and safety of this combination therapy in type 2 diabetes has been evaluated in an open-label, prospective, non-comparative multicentric, phase IV study conducted in India over a period of 6 weeks in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki. The superiority of the combination therapy and its effects on glycaemic parameters and lipid profile has been observed. A discussion of the same with brief review of literature has been presented here. (The Ind. Pract. 2005; 58(6): )
|
|
|
| |
|
